Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 25.45
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very weak growth
Data is available to registered users only
Data is available to registered users only
About
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag,...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell